Cytotoxic T-Lymphocyte antigen-4 or interleukin-10 polymorphisms as predictors of response to therapeutic intervention
OwnerLeland Yee, Jianming Tang +2inventors
InventorsLeland Yee, Jianming Tang, Richard A. Kaslow, Dirk J. van Leeuwen
Life of this patent
Estimating the term…
Abstract
A composition and process are provided for predicting the responsiveness of an individual to therapy for a pathological condition is based on detecting nucleic acid allele sequences in an interleukin-10 regulatory region or cytotoxic t-lymphocyte antigen-4 promoter or exon region of the individual. The detected nucleic acid allele is then associated with the level of therapeutic responsiveness to a pathological condition based upon genotype. Comparison across multiple alleles and regions improves the predictive nature of the process.
Claims61
A process for predicting a therapeutic response in an individual comprising the steps of:
- detecting a first nucleic acid allele in an interleukin-10 regulatory region of the individual;
- and comparing said first nucleic acid allele with a second nucleic acid allele in said interleukin-10 regulatory region associated with a known outcome of administration of interferon-α-2b and ribavirin in a pathological condition.
A process for predicting a therapeutic response in an individual comprising the steps of:
- detecting a first nucleic acid allele in an interleukin-10 regulatory region of the individual and comparing said first nucleic acid allele with a second nucleic acid allele in said interleukin-10 regulatory region associated with sustained response to therapeutic intervention in a pathological condition.
A process for predicting a therapeutic response in an individual comprising the steps of:
- detecting a first allele in a cytotoxic T-lymphocyte antigen-4 promoter or exon region of the individual;
- and comparing said first allele with a second allele in said cytotoxic T-lymphocyte antigen-4 promoter or exon associated with a known outcome of administration of interferon-α-2b and ribavirin in a pathological condition.
A process for predicting a therapeutic response in an individual comprising the steps of:
- detecting a first allele in a cytotoxic T-lymphocyte antigen-4 promoter or exon region of the individual and comparing said first allele with a second allele in said cytotoxic T-lymphocyte antigen-4 promoter or exon region associated with sustained response to therapeutic intervention in a pathological condition.
A composition comprising an oligonucleotide primer selected from the group consisting of SEQ ID NOS:1-10.
The use of oligonucleotide primers for detection of an interleukin-10 regulatory region or cytotoxic T-lymphocyte antigen-4 promoter or exon allele to predict sustained response to therapeutic intervention for a pathological condition.
The use of oligonucleotide primers for detection of an interleukin-10 regulatory region or cytotoxic T-lymphocyte antigen-4 promoter or exon allele to predict response to the interferon-α-2b and ribavirin treatment of a pathological condition.
Dependencies are inferred from the claim text.